The Predictive Value of PRECISE-DAPT Score for In-Hospital Mortality in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.


Journal

Angiology
ISSN: 1940-1574
Titre abrégé: Angiology
Pays: United States
ID NLM: 0203706

Informations de publication

Date de publication:
May 2019
Historique:
pubmed: 17 10 2018
medline: 23 4 2019
entrez: 17 10 2018
Statut: ppublish

Résumé

The PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti-Platelet Therapy (PRECISE-DAPT) score predicts the bleeding risk in patients treated with dual antiplatelet treatment after primary percutaneous coronary intervention (pPCI). This study aimed to determine the predictive value of the admission PRECISE-DAPT score for in-hospital mortality in patients with ST elevation myocardial infarction (STEMI) treated with pPCI. Of the 1418 patients enrolled, the study population was divided into 2 groups: PRECISE-DAPT score ≥25 and PRECISE-DAPT score <25. The primary goal was to determine the incidence of in-hospital all-cause mortality. In-hospital mortality was significantly higher in patients whose PRECISE-DAPT score ≥25 compared with the patients whose PRECISE-DAPT score <25 (9.4 vs 0.9%; P < .001, respectively). Both univariate and multivariate Cox proportional hazard analyses showed that the PRECISE-DAPT score is independently associated with in-hospital mortality (hazards ratio [HR]: 1.043, 95% confidence interval [CI]: 1.003-1.084; P = .035; and HR: 1.026, 95% CI: 1.004-1.048; P = .021, respectively). A pairwise comparison of receiver operating characteristic curves showed that the predictive value of the PRECISE-DAPT score with regard to in-hospital mortality was noninferior compared with the Thrombolysis in Myocardial Infarction risk score. The PRECISE-DAPT score may be a significant independent predictor of in-hospital mortality in patients with STEMI treated with pPCI.

Identifiants

pubmed: 30322265
doi: 10.1177/0003319718807057
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

440-447

Auteurs

Veysel Ozan Tanik (VO)

1 Department of Cardiology, Ankara Dişkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Tufan Cinar (T)

2 Department of Cardiology, Health Sciences University, Sultan Abdülhamid Han Training and Research Hospital, Istanbul, Turkey.

Emre Arugaslan (E)

3 Department of Cardiology, Sivas Numune Hospital, Sivas, Turkey.

Yavuz Karabag (Y)

4 Department of Cardiology, Kafkas University, Kars, Turkey.

Mert Ilker Hayiroglu (MI)

2 Department of Cardiology, Health Sciences University, Sultan Abdülhamid Han Training and Research Hospital, Istanbul, Turkey.

Metin Cagdas (M)

4 Department of Cardiology, Kafkas University, Kars, Turkey.

Ibrahim Rencuzogullari (I)

4 Department of Cardiology, Kafkas University, Kars, Turkey.

Mahmut Uluganyan (M)

5 Department of Cardiology, Bezmialem Vakif University, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH